Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  ANGLE plc    AGL   GB0034330679

ANGLE PLC

(AGL)
My previous session
Most popular
  Report  
Delayed Quote. Delayed London Stock Exchange - 03/18 12:35:11 pm
54 GBp   -2.70%
03/07ANGLE : Enrolment complete for fda clinical study
PU
02/28ANGLE : First subjects enrolled in ovarian cancer study
PU
02/25ANGLE : Customer demonstrates new use for parsortix
PU
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
03/12/2019 03/13/2019 03/14/2019 03/15/2019 03/18/2019 Date
56(c) 55.5(c) 55.5(c) 55.5(c) 54 Last
195 229 60 435 33 000 81 192 153 901 Volume
-1.75% -0.89% 0.00% 0.00% -2.70% Change
More quotes
Financials (GBP)
Sales 2019 1,30 M
EBIT 2019 -10,3 M
Net income 2019 -8,60 M
Debt 2019 -
Yield 2019 -
Sales 2020 2,70 M
EBIT 2020 -9,80 M
Net income 2020 -8,70 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 61,3x
Capi. / Sales2020 29,5x
Capitalization 79,6 M
More Financials
Company
ANGLE plc is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer... 
More about the company
Latest news on ANGLE PLC
03/07ANGLE : Enrolment complete for fda clinical study
PU
02/28ANGLE : First subjects enrolled in ovarian cancer study
PU
02/25ANGLE : Customer demonstrates new use for parsortix
PU
02/11ANGLE : Research into role of immune cells in cancer
PU
01/29ANGLE : New application for parsortix in cancer analysis
PU
01/10ANGLE : Breakthrough cancer research using parsortix
PU
2018ANGLE : Issue of LTIP Options and Share Options
PU
2018ANGLE : Leading us hematopathologist appointed as advisor
PU
2018ANGLE : Acquisition of outstanding shares
PU
2018ANGLE : Appointment of Dr Jan Groen as NED
PU
More news
Analyst Recommendations on ANGLE PLC
More recommendations
Sector news : Bio Therapeutic Drugs
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Bio Therapeutic Drugs
Chart ANGLE PLC
Duration : Period :
ANGLE plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANGLE PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Andrew D. W. Newland Chief Executive Officer & Executive Director
Garth Robert Selvey Non-Executive Chairman
Martin Cooke Director-Operations & Regulatory Affairs
Ian Francis Griffiths CFO, Secretary & Executive director
Jay Lewington Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
ANGLE PLC42.31%106
GILEAD SCIENCES4.92%83 712
VERTEX PHARMACEUTICALS13.51%48 087
REGENERON PHARMACEUTICALS10.97%44 500
GENMAB5.15%10 483
SAREPTA THERAPEUTICS INC17.62%9 457